Arkolith/Insider Trading/VRDN/Form 4

Beetham Thomas W.

Chief Operating OfficerViridian Therapeutics, Inc.\DE (VRDN) · full profile →Form 4 · filed Sep 30, 2024
Net Buying
Open-Market Buys
$117K
Open-Market Sells
$0
Net Open-Market Flow
$117K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 27, 2024Buy(P)5K$23.41$117K6K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-110485) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML